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ABSTRACT: In this study, we report a convenient analytical
method for a full-range quantification of the C-reactive protein
(CRP), a blood biomarker of infection and cardiovascular events.
We determine CRP over the entire diagnostically relevant
concentration range in undiluted human blood serum in a single
test, using a tandem giant magnetoresistance (GMR) sensor. The
tandem principle combines a sandwich assay and a competitive
assay, which allows for the discrimination of the concentration
values resulting from the multivalued dose−response curve
(“Hook” effect), which characterizes the one-step sandwich assay
at high CRP concentrations. The sensor covers a linear detection
range for CRP concentration from 3 ng/mL to 350 μg/mL, the detection limit (s/n = 3) is 1 ng/mL. The prominent features of the
chip-based method are its expanded dynamic range and low sample volume (50 μL), and the need for a short measurement time of
15 min. These figures of merit, in addition to the low detection limit equal to the established assay instrumentation, make it a viable
candidate for use in point-of-care diagnostics.
1. INTRODUCTION
CRP, mainly synthesized in the liver upon an acute
inflammatory stimulus, has been found to be a potent
biomarker of infection and pathological cardiovascular events.
The levels of C-reactive protein (CRP) are increased in many
disorders, and it is regarded as a very good predictor of disease
state, particularly cardiac risk stratification.1−3 If the levels of
CRP in serum are below 1.0 μg/mL, the risk of cardiovascular
diseases is considered low; levels between 1 and 3 μg/mL
indicate a moderate risk and levels greater than 3 μg/mL are
considered a significant indicator for chronic cardiovascular
disease, including acute coronary syndromes.4,5 Elevated levels
between 10 and 50 μg/mL can also be detected in viral
infections and late pregnancy, and levels between 50 and 200
μg/mL are typically associated with bacterial infections and
active inflammation.2,6 Values >200 μg/mL are comparatively
rare, which indicate severe health issues of the affected
individuals. Bacterial infections account for the majority of
instances of extreme CRP elevation, and mortality is high.7 To
design a universal CRP assay that is useful in diverse disease
contexts, it should span the whole concentration range, which
characterizes the clinically relevant levels of CRP, i.e., from
<1.0 to >200 μg/mL.
The most commonly utilized analytical techniques currently
employed for the quantification of CRP include the enzyme-
linked immunosorbent assay (ELISA),8 biosensors,9−13 and
lab-on-a-chip devices,14,15 with good figures of merit including
low detection limits reaching picomolar concentrations. The
methods derived from these techniques typically detect CRP in
diluted human whole blood and serum. Moreover, approved
clinical detection methods of CRP generally require expensive
analytical equipment, elaborate and time-consuming exper-
imental procedures, and trained personnel, which also make
automated and high-throughput analyses rather difficult.
To develop an alternative analytical biomarker test for
application in clinical test practice, one or more significant
benefits are required. Such benefits would include the direct
use of undiluted blood serum and direct access to the clinically
relevant concentration range of CRP in a single analysis.
Dilution is generally the preferred method to circumvent the
“Hook” effect, but it would prevent the detection of low-
abundance species. As CRP is typically determined in
conjunction with low-abundance infection biomarkers, the
dilution of the serum poses a serious practical problem. A chip
format using a sensor array for simultaneous analysis of several
biomarker species with individual dynamic ranges would not
only be capable of solving this problem but also be a promising
prerequisite for automated and rapid analysis.
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In our work toward such an improvement, we used a fully
integrated point-of-care testing (POCT) platform based upon
a giant magnetic resistance (GMR) biosensor array, combined
with microfluidic sample handling circuitry. The platform was
modified to implement a new sensor configuration, designed to
expand the dynamic range of CRP sensing. This allows for
applying undiluted samples, which not only simplifies the
existing measurement procedure but also opens pathways
toward direct and simultaneous multianalyte quantification of
both high- and low-abundance biomarkers.
In the setup, two individual sensors located on a chip array
are differentially coated to become the foundation for
complementary assay formats. On one sensor surface, a
capture antibody is immobilized for a one-step sandwich
assay, which uses a matched antibody pair: an immobilized
capture antibody and a detection antibody mixed with the
sample, both with affinity to CRP. On the other sensor, the
surface features immobilized antigens for a competitive assay,
which binds to the detection antibody in competition to CRP
present in the sample. This tandem arrangement is capable of a
single-run detection of CRP in concentration ranges typical for
a variety of medical conditions.
The one-step sandwich assay is currently the most used
format in clinical and point-of-care immunoassays due to its
high speed. The major drawback is the accessible concen-
tration range, which is commonly limited by the so-called
“Hook” effect, i.e., a multivalued dose−response relation-
ship.16,17 The “Hook” effect, only observed in one-step assays,
is caused by the excess of analyte and prevents simultaneous
binding of solid-phase and liquid-phase antibodies. Even
though the use of excess antibody postpones the “Hook”
effect to a certain extent in theory, it also greatly increases the
cost of immunoassay.
In the GMR sensor array, the sandwich assay on sensor I will
determine the full dose−response relationship, which results in
the conventionally undesirable “Hook”-shaped curve as the
concentration increases toward the upper limit, while the
competitive assay on sensor II detects at the peak point of the
“Hook” curve, which indicates whether the “Hook” effect
occurred or not in the sandwich assay. The combination of
both assays is used to determine the overall signal, which
allows for a full-range measurement. Moreover, since this
arrangement requires only 2 out of the 12 on-chip sensors per
analysis, the remaining spare channels can be utilized for
complementary assays targeting additional biomarkers.
2. MATERIALS AND METHODS
2.1. Regents and Materials. Na2HPO4, NaHCO3, KCl,
Na2CO3, NaH2PO4, NaCl, and bovine serum albumin (BSA)
were purchased from Sigma Aldrich (Merck). NHS-Biotin was
purchased from Thermo Fisher Scientific, Inc. Streptavidin-
conjugated magnetic particles (MNP, 100 nm) were purchased
from Ademtech (France). Tween-20 was purchased from
AMRESCO. A laboratory quantity of polystyrene-grafted
maleic anhydride (PS-g-MA, graft ratio 17%) was provided
free of charge by Longjia Plastics Fabrication (Jilin, China).
Heterophilic blocking reagent (HBR1) was obtained from
Scantibodies Laboratory, Inc. and heterophilic immunoglobu-
lin elimination reagent (Fapon Block: HIER-E-010) from
Fapon Biotech Inc. (China). All commercial reagents were of
analytical grade.
Antihuman CRP antibodies (Capture antibody:MCP01,
Detection antibody:MCP02) and CRP antigen were purchased
from Hangzhou Yibaixin Biotechnology Co., Ltd. (China).
Undiluted clinical serum samples were received as a donation
from the Zhujiang Hospital of Southern Medical University
(China).
The GMR immunoassay analyzer (Bosh M16) and the
polymer assay cartridge were manufactured by Dongguan Bosh
Biotechnologies, Ltd. (China). The use of this device has been
reported elsewhere.18,19
Carbonate buffer (CB, 0.1 M, pH 9.6) was used for the
immobilization of the capture antibody and capture antigen.
CBTB, used to prepare and redissolve the MNP solution, was
CB buffer spiked with 0.05% Tween-20 and 10% BSA.
Phosphate-buffered saline (PBS, 10 mM, pH 7.4) was created
by mixing NaH2PO4 and NaH2PO4. PBSB, composed of 10
mM PBS spiked with 10% BSA, was used to prepare the
labeling antibody solution. PBST, prepared by PBS spiked with
0.1% Tween-20, was used as a washing buffer. The MNP
solution, used in the assay, was washed three times and diluted
1:10 by CBTB. The detection antibody was biotinylated using
NHS-biotin20 and diluted by PBSB. Fetal bovine serum (Sigma
Aldrich) was used for the preparation of the he CRP standard
solutions.
2.2. GMR Chip Preparation. The GMR measurement is
based on the Wheatstone bridge principle. The resistance
change in the sensor is compensated, and the ratio (R − R0)/
R0 × 100 is stated as the rate of resistance change, where R is
the resistance of the GMR sensor after immunoreaction in the
specific magnetic field and R0 is the resistance of blank sensor
without the magnetic field.
Figure 1. POCT assay cartridge used in the study. A scheme of the channel architecture has been published elsewhere.19 (A) Schematic view of the
full microfluidic sample handling device with on-chip sample wells. (B) GMR sensor chip contained in the cartridge, featuring 12 individual sensors.
(C−E) Successive magnifications of a single GMR sensor array chip, obtained by optical microscopy and scanning electron microscopy (SEM).
The two selected sensor units used in tandem are marked by a blue square in (C).
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The reagents needed in the array were supplied to the
corresponding cartridge wells (sample, washing buffer, MNP
buffer) (Figure 1A). The GMR chip18 (2.66 mm × 1.62 mm)
containing 12 individual GMR sensors (120 μm × 120 μm
each) (Figure 1B) was surface-modified and combined with
the cartridge body (top structure with wells) and an
intermediate channel layer (microfluidic circuitry) prior to
use. A beneficial feature of the GMR sensor array is the ability
to perform parallel analyses, which is useful for the tandem
assay, but also for performing repeat measurements and
simultaneous analyses of additional biomarkers. In this
research, two individual sensors from this array (Figure 1C−
E) were modified as a sandwich array sensor and a competitive
array sensor. Note that the top corners are marked, which is
necessary for the nanoplotter to determine the positions of the
sensors. These points are optically autorecognized by the
plotter.
The GMR chip surface was coated with PS-g-MAH in a 1%
(w/v) solution in toluene via spin coating (EZ-4 spin coater,
Zhengzhou CY Scientific Instrument Co., Ltd., I: 800 rpm, 30
s, II: 2000 rpm, 60 s) and annealed at 70 °C for 10 min in a
laboratory convection oven (ZD-85, Jintan Jincheng Guosheng
Experimental Instrument Co. Ltd., China) (Figure 2A). The
CRP capture antibody and antigen solutions were deposited
onto the sensors using an NP 2.1 Nano-Plotter (GeSiM,
Germany) and thereafter incubated for 30 min at 37 °C and
70% humidity. The antibody (sensor I) and antigen (sensor II)
molecules are chemically conjugated to the MAH function-
alities on the surface.21 The unreacted PS-g-MAH will be
directly deactivated upon incubation at 37 °C and high
humidity, so a blocking step is unnecessary. The detection
antibody solution (10 μL) and the MNP solution (10 μL)
were pipetted to the designated reservoirs of the intermediate
channel layer and freeze-dried. Subsequently, the cartridge was
assembled. Since some proteins in human serum may undergo
nonspecific binding, we have solved this problem by preadding
commercial blockers (HBR1: 200 μg/mL × 5 μL & Fapon
Blocker: 250 μg/mL × 5 μL) to the sample well, followed by
freeze-drying.
2.3. Immunoassay Procedure. For the purpose of
expanding the measurement range, covering the concentration
range relevant for clinical analysis, we combined a CRP
antigen-modified sensor as a competitive array sensor with a
sensor modified for a sandwich assay (Figure 2A−D). In the
presence of low concentrations of antigen, the sandwich array
sensor I, which uses a one-step antibody−antigen binding
reaction, generates a response signal that increases with
concentration. In contrast, in the presence of high concen-
trations of antigen, the sandwich array sensor signal decreases
with the CRP concentration. Sensor II, modified for the
Figure 2. Assay protocol for detecting the “Hook” effect to quantify CRP. (A) Surface modification. Sensor I: sandwich array sensor. Sensor II:
indirect competitive assay sensor. (B) One-step antibody−antigen reaction after sample loading. (C) Biotin-labeled detection antibody or free
antigen binding. (D) Magnetic particle binding and detection. Ws: washing step.
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competitive immunoassay, is utilized to monitor at which
concentration the “Hook” effect occurs. The two signals are
combined and processed to establish a unique dose−response
relationship. The assay protocol (Figure 2A−D) comprises the
first step of an immunoreaction of (sample or standard)
antigen with detection antibodies (Figure 2B). On the surface
of sensor I, the antigen−antibody pair attaches to the capture
antibodies, forming the immunoassay sandwich (37 °C, 7 min;
Figure 3. Principle of data processing. (A) Calibration curve obtained with external standards from sensor I, displaying the “Hook” effect
(multivalued dose−response curve). (B) Indicator curve from sensor II. The measured signal intensity decreases with analyte concentration
(competitive assay). The red star denotes the indicator point assigned for determining whether the “Hook” effect has occurred or not. (C)
Superposition of the two calibration curves for the determination of the position of the indicator point.
Figure 4. Optimization of the sensor signals. (A) Dependence of the signal magnitude (sensor I) on the concentration of the capture antibody (n =
4). The inset refers to the analyte (CRP) concentrations used to detect the point of saturation over the entire concentration range. (B)
Dependence of the signal magnitude (sensor I) on the concentration of the detection antibody (n = 1). The inset refers to the different
concentrations of detection antibody used to determine a hook-shaped curve that covers the entire concentration range of interest. (C)
Dependence of the signal magnitude (sensor II) on the concentration of surface-immobilized antigen (n = 1). The inset refers to the concentrations
of the capture antigen solution used to prepare the sensor surface.
Figure 5. Optimization of the reaction time (n = 4). (A) Sandwich assay (sensor I). (B) Competitive assay (sensor II).
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Figure 2C). Simultaneously, excess detection antibody binds to
the antigen on the surface of sensor II (Figure 2C). Thereafter,
the binding to avidin-coated magnetic nanoparticles occurs (6
min at 37 °C; Figure 2D). Washing steps (flow rate 50 μL/
min, 1 min at 37 °C) are applied before and after the MNP
binding step. The captured MNP (Figure 2D) are detected in
the final step by the GMR sensors. Their output signals are
processed, and calibration curves as well as the CRP
concentration in the sample are obtained. The total analysis
time is 15 min.
2.4. Data Processing. For the creation of the calibration
curves, four reference measurements were performed for each
concentration point, and means/standard deviations were
calculated. Ninety-one patient samples were analyzed in total;
one measurement was performed per patient sample.
By means of the sensor II signal, we detect the turning point
in the “Hook”-shaped dose−response curve to discriminate
between the low- and high-concentration situations (Figure 3).
Standard curve I was used to quantify the concentration of
CRP before the “Hook” effect occurs, while standard curve II
was used to quantify the concentration of CRP after the peak
point of the dose−response curve (Figure 3A). Using the
established standard curves, we first located an indicator point
according to the signal recorded with sensor II (Figure 3B).
The indicator point is chosen by the superposition of both
calibration curves (Figure 3C). The full indicator curve is not
used for quantification in the usual manner of external
calibration, only the indicator point is used. If the measured
value is higher than the value of the indicator point, the signal
from sensor I is used with standard curve I (Figure 3A, orange
line). In the other case with the measured value less than the
value of the indicator point, the signal from sensor II is used
with standard curve II (Figure 3A, brown line).
2.5. Fitting Software and Algorithm. All standard curves
were fitted by the four-parameter logistic model (y = A2 + (A1
− A2)/(1 + (x/x0)p)),22 using Origin 9.1 software.
3. RESULTS AND DISCUSSION
To establish optimal values for all assay components as well as
experimental conditions, (a) the concentrations of capture and
detection antibody and (b) the amount of surface-immobilized
antigen (sensor II) were optimized first. Thereafter, the
reaction times of both integrated assays were optimized
individually. Calibration curves for sensor I (21 external
standards with n = 4) and sensor II (21 external standards with
n = 4) were recorded and fitted to the selected model.
Afterward, 91-patient samples were measured (n = 1) and
validated with an equal number of samples on Roche Cobas
C501.
3.1. Optimization of Detection of CRP. 3.1.1. Concen-
tration of Antibody and Antigen. The influence of the
capture antibody concentration on the immune reaction of a
sandwich assay was determined in the presence of 0.05, 3, and
100 μg/mL CRP (Figure 4A). The rate of resistance changes
saturated as the concentration of the capture antibody
exceeded 50 μg/mL. Accordingly, 50 μg/mL capture antibody
was used in the assay.
The influence of detection antibody concentration on the
sensor I signal (sandwich assay) was investigated with respect
to the detection antibody concentration (1, 10, and 100 μg/
mL; Figure 4B). Since both sensors are subjected to the same
detection antibody solution, they cannot be individually
optimized. The determination of the inversion point in the
calibration curve is fundamental; therefore, the detection
antibody concentration is optimized for sensor I. The optimal
relationship that covers the full clinical range while requiring
the lowest amount of detection antibody was found at a
concentration of 10 μg/mL. In principle, as the blue line in
Figure 4B suggests, up to a CRP concentration of 10 μg/mL,
the assay could be run using a single sensor. However, the cost
of the detection antibody decides the overall cost of a single
assay so that there is no apparent benefit. Moreover, at very
high CRP concentrations, the sensor response intensity is low,
close to the limit of quantification (LOQ). To further optimize
the assay for analytical situations specifically at the high end of
the concentration range, a detection antibody concentration
somewhere in between 10 and 100 μg/mL could be applied.
Some mechanistic aspects concerning the appearance of the
multivalued calibration curves in dependence on detection
antibody concentration were reported earlier by Fernando et
al.16
The optimal concentration of the CRP capture antigen for
the signal intensity arising from the immune reaction of the
competitive assay (sensor II), which matches the response of
sensor I, was determined as 2 μg/mL (Figure 4C). To further
optimize the assay for analytical situations that give a better
indicator, a capture antigen concentration somewhere between
0.2 and 2 μg/mL could be applied.
One additional factor that would possibly benefit from
optimization is the quality of the functionalized sensor
surfaces, which depends on a variety of process parameters.
The concentration of the PS-g-MAH solution, solvent,
parameters of spin coating, and drying conditions could have
an influence on the final functionalization and can be made the
subject of optimization. Currently, we do not have established
information on surface-related parameters, such as the number
and density of antibodies, their distribution, or molecular
Table 1. Precision of the Assay (n = 80)













5 5.012 0.437 8.71 0.465 9.28
100 99.41 8.485 8.54 7.359 7.40
Table 2. Long-Term Stability of the Assay (n = 6)
time (d) 0 3 5 7
conc. (μg/mL) 5 100 5 100 5 100 5 100
mean (μg/mL) 5.10 99.45 5.07 102.3 4.98 98.87 4.71 95.11
recovery (%) 102.0 99.5 101.4 102.3 99.6 98.9 94.2 95.1
SD (μg/mL) 0.43 7.12 0.30 9.35 0.36 5.86 0.28 6.66
RSD (%) 8.36 7.16 5.96 9.13 7.22 5.93 5.91 7.00
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conformation, and orientation or shape on the sensor surface.
These aspects are still under investigation.
3.1.2. Reaction Time. The reaction times for the binding of
capture antibody to the detection antibody-bound CRP, and
for the reaction of the remaining unreacted detection antibody
to the sensor surfaces, are in this assay key performance
parameters (cf. Figure 2B,C). Figure 5 shows for the optimized
conditions of antibody and antigen concentrations, established
as described above, the influence of the two reaction times on
the sensor signals for the sandwich assay (Figure 5A) and the
competitive assay (Figure 5B). The CRP concentrations of
0.05 (black lines), 3 (red lines), and 100 μg/mL (blue lines)
were investigated. We established that at t = 7 min, both sensor
responses reached a maximum, and used this as reaction time
for the measurements.
A time for particle binding (cf. Figure 2D) of 6 min was used
without further optimization.23 Furthermore, a 1 min washing
step (50 μL total volume) prior to MNP binding was applied
to remove unreacted assay components, and a 1 min washing
step (50 μL total volume) after MNP binding was applied to
remove the unbinding MNP.
3.2. Precision and Long-Term Stability and of the
Assay. The numerical precision values of the measurements
for a population n = 80, split into two concentration levels, are
presented in Table 1. The measurement period is 20
consecutive days with two measurements per day and
concentration level. The assay cartridges used were newly
fabricated on the day of the measurement. The measurements
on the same day are denominated as intra-assay, all
measurements as interassay.
We have also investigated the long-term stability of the
reagent-loaded cartridge by incubating it at 37 °C over a 7-day
period (Table 2). The recovery (94.2%−100.23) and relative
standard deviation (RSD) < 10% (n = 6) obtained from this
accelerated aging test suggest that the assay can maintain
function for several months at 4 °C.
3.3. Establishment of Standard Curves. All standard
curves were fitted by the four-parameter logistic model (y = A2
+ (A1 − A2)/(1 + (x/x0)p)) (Figure 6A). For standard curve I
(black line), A1 = 0.11964, A2 = 3.05252, x0 = 0.06783, p =
0.73045, R2 = 0.9988. For standard curve II (red line), A1 =
3.0816, A2 = −0.04743, x0 = 17.27685, p = 0.58217, R2 =
0.9998. For the indicator curve (blue line), A1 = 1.86524, A2 =
0.02144, x0 = 3.43843, p = 1.64857, R
2 = 0.9995.
The three curves were then used for the quantification of
CRP in the patient samples. Under the applied conditions, the
“Hook” effect began to occur on sensor I (sandwich assay) at a
CRP concentration of 0.781 μg/mL. The GMR signal on
sensor II (competitive assay) was measured at that point as
1.745%, which was accordingly set as the indicator point of the
assay.
3.4. Measurement and Validation. Validation of the
measurements obtained with the GMR sensor device was
performed against the Roche Cobas C501 optical assay (Figure
6B,C). Fitness analysis (n = 91) resulted in the following
parameters for the data set, covering the concentration range
between 3 and 350 μg/mL: y = 1.003x − 0.0104; r = 0.9881
(Figure 6B). In Figure 6C, the Bland−Altman plot of the
relative differences between the data sets of the two compared
assays is displayed. The mean relative difference is 1.96%
(−10.825−11.208%, 95% confidence limit). A statistically
significant bias between the two assays is not present.
4. CONCLUSIONS
We have developed and characterized the analytical perform-
ance of a tandem GMR sensor immunoassay for the biomarker
CRP in human blood, featuring two different formats in an
automated microfluidic sample handling cartridge. The
combination enables measurement over the full clinically
relevant concentration range. This means that the dilution of
blood plasma samples is not required, which opens new
possibilities for one-shot multimarker detection without
compromising on low-abundance biomarkers.
Differential antibody/antigen coating of the individual GMR
sensors was achieved by surface modification using the
functional polymer PS-g-MAH, using a combination of spin-
coating (polymer) and nanoplotting (proteins). The avail-
ability of the grafting polymer samples for research purposes is
unfortunately still subject to a request to the manufacturer
since the material is currently only commercially produced in
industrial quantities.
The detection of the hook curve feature is easily applicable
to a variety of different antibodies, giving the new assay
concept a wide application scope, particularly for the POC
diagnostics. This is supported by the assay’s low cost, short
measurement time of ∼15 min, small sample size (50 μL), long
shelf-life, and simple operation, which are all additional
benefits. We successfully validated the tandem sensor assay
against a commercial system, which established that the
method has comparable figures of merit (e.g., limit of detection
(LOD), LOQ) and would therefore be suitable for application
in clinical testing. Reuse approaches could be investigated to
satisfy sustainability demands, requiring a careful analysis of
possible cross-contamination.
Figure 6. (A) Standard curves of the one-step sandwich assay combined with a competitive immunoassay for CRP detection (n = 4). (B, C)
Comparison between the sensor and a commercial reference assay: the fitness analysis (B) and the Bland−Altman analysis for the validation of the
GMR assay against the Roche Cobas C501 assay (C).
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